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Abstract
Fish consumption is considered health beneficial as it decreases cardiovascular disease (CVD)-risk through effects on plasma
lipids and inflammation. We investigated a salmon protein hydrolysate (SPH) that is hypothesized to influence lipid
metabolism and to have anti-atherosclerotic and anti-inflammatory properties. 24 female apolipoprotein (apo) E2/2 mice
were divided into two groups and fed a high-fat diet with or without 5% (w/w) SPH for 12 weeks. The atherosclerotic plaque
area in aortic sinus and arch, plasma lipid profile, fatty acid composition, hepatic enzyme activities and gene expression
were determined. A significantly reduced atherosclerotic plaque area in the aortic arch and aortic sinus was found in the 12
apoE2/2 mice fed 5% SPH for 12 weeks compared to the 12 casein-fed control mice. Immunohistochemical characterization
of atherosclerotic lesions in aortic sinus displayed no differences in plaque composition between mice fed SPH compared to
controls. However, reduced mRNA level of Icam1 in the aortic arch was found. The plasma content of arachidonic acid
(C20:4n-6) and oleic acid (C18:1n-9) were increased and decreased, respectively. SPH-feeding decreased the plasma
concentration of IL-1b, IL-6, TNF-a and GM-CSF, whereas plasma cholesterol and triacylglycerols (TAG) were unchanged,
accompanied by unchanged mitochondrial fatty acid oxidation and acyl-CoA:cholesterol acyltransferase (ACAT)-activity.
These data show that a 5% (w/w) SPH diet reduces atherosclerosis in apoE2/2 mice and attenuate risk factors related to
atherosclerotic disorders by acting both at vascular and systemic levels, and not directly related to changes in plasma lipids
or fatty acids.
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Introduction
Cardiovascular disease (CVD) is responsible for approximately
16–17 million deaths annually, making it the leading cause of
mortality in Western countries [1,2]. The disease encompasses
conditions such as coronary artery disease, carotid and cerebral
atherosclerotic disease and peripheral artery atherosclerosis
resulting in chronic and acute ischemia in affected organs. The
underlying pathological process is lipid accumulation leading to
atherosclerosis, a slowly progressing chronic disorder of large and
medium-sized arteries that can lead to intravascular thrombosis
with subsequent development of complications like myocardial
infarction (MI), stroke and acute ischemia of the limb [3]. In the
last years, inflammation has emerged as an additional key factor in
the development of atherosclerosis and seems to be involved in all
stages, from the small inflammatory infiltrate in the early lesions,
to the inflammatory phenotype characterizing an unstable and
rupture-prone atherosclerotic lesion [4]. In fact, today atheroscle-
rosis is regarded as a disorder characterized by a status of non-
resolved inflammation, with bidirectional interaction between
lipids and inflammation as a major phenotype. Inflammation in
atherosclerosis leads to activation of endothelial cells, enhanced
expression of adhesion molecules, inflammatory cytokines and
macrophage accumulation.
Liver is the main organ regulating lipid metabolism, affecting
blood lipids, especially plasma triacylglycerols (TAG) [5]. Recent-
ly, investigators have suggested that the liver plays a key role in the
inflammatory state of an individual [6,7], and that dietary
cholesterol absorbed by the liver contributes to inflammation
[8]. Research into atherosclerosis has led to many compelling
discoveries about the mechanisms of the disease and together with
lipid abnormalities and chronic inflammation, oxidative stress has
a crucial involvement in the initiation and progression of
atherosclerosis [9].
Improvement of life style and dietary habits can reduce some
risk factors such as high levels of low density lipoprotein (LDL)-
cholesterol, TAG and inflammatory molecules [10]. Fish con-
sumption is consider health beneficial as it lowers plasma lipids
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and attenuates inflammation [11]. This is linked to the long-
chained n-3 polyunsaturated fatty acids (PUFA) content, in
particular eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA). However, fish protein is a rich source of bioactive peptides
with valuable nutraceutical and pharmaceutical potentials beyond
that of n-3 PUFAs [11]. Fish protein hydrolysates are generated by
enzymatic conversion of fish proteins into smaller peptides, which
normally contain 2–20 amino acids. In recent years, fish protein
hydrolysates have attracted much attention from food scientists
due to a highly balanced amino acid composition, as well as the
presence of bioactive peptides [12]. The organic acid taurine is
mainly found in marine proteins, and is suggested to induce
cholesterol-lowering effect by increasing excretion through bile,
thus potentially exerting an anti-atherosclerotic effect [13]. Recent
studies show TAG-lowering effects [14,15], antioxidant capacity
[12], antihypertensive [11] and cholesterol-lowering effects
[16,17], and potential to reduce markers of reactive oxygen
species [18] from fish protein. Therefore, fish protein hydrolysates
have been implicated in several processes with potential anti-
atherogenic effects. In this study, we examined the anti-athero-
sclerotic potential of a salmon protein hydrolysate (SPH) on
atherosclerotic development in apolipoprotein E-knockout
(apoE2/2) mice.
Materials and Methods
Experimental Design
The study was conducted according to national (D.L. 116, G.U.
Suppl. 40, February 18, 1992, Circolare No. 8, G.U July 1994)
and international laws and policies (EEC Council Directive 2010/
63, September 22, 2010: Guide for the Care and Use of
Laboratory Animals, United States National Research Council,
2011). The Italian Ministry of Health approved the protocol (nu
04/2012).
24 female apoE2/2 mice from the breeding strain C57BL/6, 8
weeks old, were purchased from Charles River Laboratories
(Calco, Italy), and kept under standard laboratory conditions (12
hours light cycle, temperature 2261uC, humidity 5565%), with
free access to standard chow and tap water. After 1 week of
acclimatization under these conditions, mice were randomly
divided into two groups of 12 mice. Although apoE2/2 mice
spontaneously develop atherosclerosis, both groups were fed a
high-fat diet (23.7% w/w) consisting of 21,3% lard (Ten Kate
Vetten BV, Musselkanaal, Netherlands) and 2.4% soy oil (Dyets.
Inc., Betlehem, PA, USA) to accelerate the atherosclerotic
formation. The control diet contained 21% w/w casein as protein
source, whereas 5% casein was replaced with an equal amount of
salmon protein hydrolysate (SPH) (Marine Bioproducts, Storebø,
Norway) in the intervention diet. The SPH was produced by
enzymatic hydrolysis from salmon by-products (spine) using
controlled autolysis with an alkaline protease and a neutral
protease, and the resulting protein hydrolysate was then subjected
to a second enzymatic treatment with an acid protease A. The
final hydrolysate was fractionated using micro- and ultra- filtration
and the size distribution of the peptides was analysed. The final
preparation consisted of peptides ,1200 Da and 25% of the
peptides were below 200 Da. The diets were isocaloric containing
21% protein, 24% fat, 42% carbohydrates and 6% micronutrients,
and administered for 12 weeks. Other diet ingredients were from
Dyets. Inc., and the full composition of the diets, as well as amino
acid composition, is given in Table S1.
Harvesting of Tissue
During the treatment period, blood samples were collected at
day 1 and after 77 days from the retro-orbital plexus into tubes
containing 0.1% (w/v) EDTA after an overnight fast. Blood
samples were chilled on ice for at least 15 minutes and stored at 2
80uC until analyses.
After 12 weeks of treatment, mice were sacrificed under general
anaesthesia with 2% isoflurane (Forane, from Abbot Laboratories
Ltd, Illinois, USA) and blood was removed by perfusion with
phosphate-buffered saline (PBS). Aorta was rapidly dissected from
the aortic root to the iliac bifurcation, periadventitial fat and
connective tissue was removed as much as possible. Aorta was
longitudinally opened pinned flat on a black wax surface in ice-
cold PBS, photographed unstained [19] for subsequent plaque
quantification (see En face analysis), and then immediately put in a
tissue-freezing medium, snap-frozen in liquid nitrogen and stored
at 280uC. For histological/immunohistochemical analysis, six
hearts from each group were removed, fixed in 10% formalin for
30 min and transferred into PBS containing 20% sucrose (w/v)
overnight at 4uC before being embedded in OCT compound
(Sakura Finetek Euope B.V., Alphen aan den Rijn, The Nether-
lands) and stored at280uC. An equal subset of hearts and all livers
were immediately snap-frozen in liquid nitrogen for subsequent
analyses.
En Face Analysis
Aorta images were recorded with a stereomicroscope-dedicated
camera (IC80 HD camera, MZ6 microscope, Leica Microsystems,
Germany) and analysed using ImageJ image processing program
(http://rsb.info.nih.gov/ij/). An operator blinded to dietary
treatment quantified the atherosclerotic plaques.
Aortic Sinus Histology/immunohistochemistry
Serial cryosections (7 mm thick) of the aortic sinus were cut.
Approximately 25 slides with 3 cryosections/slide were obtained,
spanning the three cusps of the aortic valves. Every fifth slide was
fixed and stained with hematoxylin and eosin (Bio-Optica, Milano,
Italy) to detect plaque area. Plaque area was calculated as the
mean area of those sections showing the three cusps of the aortic
valves. Adjacent slides were stained to characterize plaque
composition. Specifically, Masson’s Trichrome (04-010802, Bio-
Optica, Milano, Italy) was used to detect extracellular matrix
deposition and Oil red O staining (Sigma-Aldrich, St. Louis, MO,
USA) was used to detect intraplaque neutral lipids.
Macrophages and T-lymphocytes were detected using an anti-
F4/80 antibody (ab6640, Abcam, Cambridge, UK), and an anti-
CD3 antibody (ab16669, Abcam, Cambridge, UK), respectively.
A biotinylated secondary antibody was used for streptavidine-
biotin-complex peroxidase staining (Vectastain Abc Kit, Vector
Laboratories, Peterborough, UK). 3,39-Diaminobenzidine was
used as chromogen (Sigma-Aldrich, St. Louis, MO, USA), and
sections were counterstained with hematoxylin (Gill’s Hematox-
ylin, Bio-Optica, Milano, Italy). To acquire and process digital
images an Aperio ScanScope GL Slide Scanner (Aperio Technol-
ogies, Vista, CA, USA), equipped with a Nikon 206/0.75 Plan
Apochromat objective producing a 0.25 mm/pixel scanning
resolution with a 406magnification and the Aperio ImageScope
software (version 8.2.5.1263) was used. A blinded operator to the
study quantified plaque area, extracellular matrix and lipid
deposition, as well as inflammatory cell infiltrate. The amount of
extracellular matrix, lipids, macrophages and T-lymphocytes was
expressed as percent of the stained area over the total plaque area.
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Plasma Lipid and Fatty Acid Composition Measurements
Enzymatically measurements of plasma lipids were performed
with an automated method for direct measurement of lipids on a
Hitachi 917 system (Roche Diagnostics GmbH, Mannheim,
Germany) using triacylglycerol (GPO-PAP), total- and free
cholesterol kits (CHOD-PAP) from Roche Diagnostics, and
phospholipids FS kit and a non-esterified fatty acids (NEFA) kit
from DiaSys (Diagnostic Systems GmbH, Holzheim, Germany).
Total plasma fatty acid composition was analyzed as previously
described [20].
Gene Expression in Liver, Heart and Aorta
Total cellular RNA was purified from 20 mg liver, total
homogenized heart and pooled aorta samples from six mice using
the RNeasy kit and the protocol for purification of total RNA from
animal cells and fibrous tissue (Qiagen GmbH, Hilden, Germany),
as described by Vigerust et al. and Strand et al., respectively
[21,22]. cDNA was obtained as described by Strand et al. [22].
Real-time PCR was performed on an ABI prism 7900 H sequence
detection system (Applied Biosystems, Foster City, CA, USA) using
384-well multiply PCR plates (Sarstedt Inc., Newton, NC, USA)
and probes and primers from Applied Biosystems, Foster City,
CA, USA as described by Strand et al. [22]. The primers used are
listed in Table S2. Six different reference genes were included for
liver: 18s (Kit-FAM-TAMRA (Reference RT-CKFT-18s)) from
Eurogentec (Seraing, Belgium), ribosomal protein, large, P0
(Rplp0, AX-061958-00-0100), hypoxanthine guanine phosphor-
ibosyltransferase 1 (Hprt1, AX-045271-00), ribosomal protein,
large, 32 (Rpl32, AX-055111-00), polymerase (RNA)II(DNA
directed) polypeptide A, (Polr2a, AX-046005-00) and TATA-box
binding protein (Tbp, AX-041188-00) all five from Thermo Fisher
Scientific Inc. (Waltham, MA, USA). For the heart 18s, Rplp0 and
Hprt1 were used, and for aorta 18s, Rplp0, Rpl32 and Hprt1. The
software GeNorm (http://www.gene-quantification.de/hkg.html)
was used to evaluate the reference genes, and data normalized to
Rplp0 and Rpl32 for liver, Hprt1 for heart and Rplp0 and Hprt1 for
aorta, are presented.
Hepatic Enzyme Activities
Livers were homogenized and the post-nuclear fraction isolated
as described earlier [23]. The assay for carnitine palmitoyltrans-
ferase (CPT)-2 was performed according to Bremer [24] and
Skorve et al. [25], but with some modifications: the reaction mix
contained 17.5 mM HEPES pH 7.5, 52.5 mM KCl, 5 mM KCN,
100 mM palmitoyl-CoA and 0.01% Triton X-100. The reaction
was initiated with 100 mM [methyl-14C]-L-carnitine (1100 cpm/
gmol), and 35 mg total protein was used. Palmitoyl-CoA oxidation
was measured in the post-nuclear fraction from liver as acid-
soluble products [26]. The activity of fatty acyl-CoA oxidase
(ACOX)-1 and acyl-CoA: cholesterol transferase (ACAT) were
measured in post-nuclear fractions as described by Madsen et al.
[26] and Field et al. [27], respectively.
Measurements of Plasma Inflammatory Markers
Levels of interleukin (IL)-1b, IL-6, IL-10, tumor necrosis factor
(TNF)-a and granulocyte-macrophage colony-stimulating factor
(GM-CSF) were analyzed on plasma samples collected at day 77 of
treatment by Multiplex suspension technology using a customized
Bio-Plex Pro Mouse assay (Bio-Rad Laboratories, Hercules, CA).
Statistical Analysis
The results are presented as mean with standard deviation (SD)
for 4–12 mice per group. Normal distribution was assessed by the
Kolmogorov-Smirnov test. Unpaired Student’s t-test was used to
evaluate statistical differences between groups; Mann-Whitney test
was applied when data were not normally distributed. A value of
P,0.05 was considered statistically significant. Statistical analyses
were performed using Prism Software (GraphPad Prism version
5.0; GraphPad Prism, San Diego, CA, USA).
Results
The SPH-diet Decreased Atherosclerotic Plaque
Development
After 12 weeks on a high-fat diet, 5% SPH-fed mice displayed a
weight gain similar to the control group. At sacrifice, the average
weight gain was 5.9861.78 g (mean 6 SD) in controls and
5.0460.88 g in SPH mice (P.0.05). A significantly lower plaque
development was observed in the aortic arch in SPH-fed mice
compared to control mice (0.5560.33 vs. 1.6360.996106 mm2;
Fig. 1, corresponding to 0.9160.55 vs. 2.7261.72% of the aortic
surface covered by plaque). There were no differences in thoracic
(1.0860.47 vs. 0.8560.416106 mm2; Fig. 1, corresponding to
1.7160.84 vs. 1.4160.68% of the aortic surface covered by
plaque) or abdominal aorta sections (0.8160.53 vs.
0.7860.536106 mm2; Fig. 1, corresponding to 1.3660.89 vs.
1.2960.88% of the aortic surface covered by plaque).
A significant reduction in lesion area was observed at the aortic
sinus of mice fed SPH compared to controls (1.2760.416105 mm2
vs. 2.0260.316105 mm2; Fig. 2A–C). Plaque stability is an
important factor concerning the severity of atherosclerosis.
However, histological/immunohistochemical characterization of
atherosclerotic lesions displayed no significant difference in plaque
composition between mice fed SPH and controls, showing a
comparable percentage of area occupied by extracellular matrix
(34.5660.56% vs. 30.31618.25%; Fig. 2D–F), lipids
(74.0667.48% vs. 79.6866.45%; Fig. 2G–I), macrophages
(64.4764.47% vs. 60.5763.71%; Fig. 2J–L), and lymphocytes
(27.36611.73% vs. 22.6267.24%; Fig. 2M–O).
Inflammation and oxidative stress are strong contributing
factors in atherosclerosis, thus gene expression of inflammatory
markers and redox regulators in aorta and heart were measured.
Accompanied by decreased plaque area in sinus and aortic arch,
mRNA level of intracellular adhesion molecule (Icam1) was
decreased with 59.54%, in addition to a small decrease in
expression of vascular cell adhesion molecule (Vcam1) and
monocyte chemoattractant protein 1 (Mcp1) in pooled aortic arch
from six mice, whereas mRNA level of inducible nitric oxidase 2
(Nos2) was not modified by the dietary treatment with SPH
(Fig. 3A). In contrast, no changes were found in gene expression
in the heart of Icam1, Vcam1, Mcp1, Nos2 or Tnfa, nor of the
antioxidant markers superoxide dismutase 1, soluble (Sod1),
superoxide dismutase 2, mitochondrial (Sod2) or catalase (Cat)
(data not shown).
Decreased Plasma Levels of Inflammatory Markers
To further elucidate the potential anti-inflammatory effects of
SPH in this experimental model of atherosclerosis, we examined
plasma levels of inflammatory mediators. As shown in Fig. 3B–F,
levels of IL-1b, IL-6, IL-10, TNF-a and GM-CSF were
significantly lower in SPH-treated mice compared to controls.
SPH-intervention Affected Hepatic mRNA Expression
Involved in Lipogenesis
Hyperlipidemia is closely linked to atherosclerotic development.
Liver is the main tissue regulating lipid metabolism, and
mitochondrial b-oxidation is important in regulating plasma
Salmon Protein Hydrolysate Reduces Atherosclerosis
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TAG. Hepatic gene expression showed a significant downregula-
tion in mRNA level of Acaca in SPH-fed mice (Fig. 4A). Moreover,
the mRNA level of Scd1 was significantly downregulated as well
(Fig. 4B).
Noteworthy, SPH administration had no effect on palmitoyl-
CoA oxidation in the presence and absence of malonyl-CoA (Fig.
A in Table S1), nor on mitochondrial and peroxisomal fatty acid
oxidation as the enzyme activities of CPT2 and ACOX1,
respectively, were unchanged (Fig. B and C in Figure S1).
ACAT activity, involved in cholesteryl ester synthesis, was also
unaltered (Fig. D in Figure S1).
Effects of SPH on Lipid Concentration and Fatty Acid
Composition in Plasma
In order to evaluate the effect of SPH treatment on plasma lipid
concentration, blood was collected for enzymatic measurement of
lipid profile after 77 days of dietary treatment. As shown in
Table 1, plasma total- and free-cholesterol, as well as TAG,
cholesteryl esters and phospholipids concentrations displayed
comparable levels between SPH-group and control group at the
end of treatment period, whereas NEFAs increased in SPH-fed
mice vs. controls (Table 1). Moreover, no difference was observed
between the two groups in the relative amount of saturated fatty
acids (SFA) (Table 2). The relative amount of monounsaturated
fatty acids (MUFA) in SPH-fed mice was slightly lower than
controls at day 77, mainly due to a small decrease in 18:1n-9 (oleic
acid) and 18:1n-7 (vaccenic acid) (Table 2). Total n-6 PUFAs
displayed a higher amount after 77 days of treatment in the SPH-
group, probably due to the increase of C18:2n-6 (linoleic acid) and
C20:4n-6 (arachidonic acid) compared to controls. In contrast, no
differences were detected in the weight % of n-3 PUFAs between
the two groups. As a consequence, a small reduction in n-3/n-6
ratio was observed after 77 days. Overall, the effect of the SPH-
diet on plasma lipids and fatty acids was modest.
Discussion
Fish intake is inversely correlated to CVD-risk factors in both
observational and clinical interventional trials [28]. Particular
attention has been drawn to the cardio-protective effects of fatty
fish species with high levels of omega-3 PUFAs through their lipid-
lowering, anti-inflammatory, antiplatelet and antiarrhythmic
mechanisms [29,30]. Marine organisms are also a rich source of
bioactive proteins and peptides that may induce health benefits
through antihypertensive and antioxidative [28], immunomodu-
lating [31] and lipid-lowering effects [14,17]. Thus, marine
proteins and peptides have been shown to influence the two
major risks for atherosclerotic development, namely hyperlipid-
emia and inflammation. Therefore, it was of interest to investigate
a potential anti-atherosclerotic effect of SPH-diet in apoE2/2mice
fed a high-fat diet. Although these mice spontaneously develop
atherosclerosis on a standard rodent diet, a high-fat diet regimen,
Figure 1. Atherosclerotic plaque level in apoE2/2 mice fed a high-fat diet (control) or a diet with 5% SPH. After 12 weeks of dietary
treatment, whole aorta was collected and en-face analysis was performed to quantify aortic surface covered by atherosclerotic plaques. Bars represent
means 6 SD of 12 mice for each diet. Unpaired t-test was used to detect statistical significance (*P,0.05).
doi:10.1371/journal.pone.0097598.g001
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combined with female mice, was preferred to accelerate the
progression. We showed that apoE2/2 mice fed a high-fat diet
containing 5% (w/w) SPH for 12 weeks developed less athero-
sclerotic plaques compared to controls. In particular, we observed
a significant reduction of plaque area in the aortic arch as well as
in the aortic sinus. The pathophysiological complication of
atherosclerosis is plaque rupture causing heart attack and stroke
in humans. Vulnerability of plaque rupture is an important
element in the fatal outcomes of atherosclerosis, and content and
stability of the plaque is therefore of interest. However, there was
no change in aortic sinus plaque composition of connective tissue,
macrophages or lymphocytes, indicating that SPH had no effect
on plaque stability. Unfortunately, apoE2/2 mice are not
susceptible to the progress of plaque rupture unless treated with
a high-fat diet for over a year, thus studying plaque stability in this
model is limited.
During plaque development, accumulation of adhesion mole-
cules contributes to foam cell formation. In addition to decreased
plaque area in aortic arch, a decrease in expression of the adhesion
molecule Icam1, as well as a small reduction in Vcam1 and the
chemokine Mcp1, was detected in pooled aortic arch of SPH-
treated mice, suggesting a local anti-atherosclerotic effect of the
SPH-diet. The plaque area decreased, but no reduction in number
of macrophages was observed with immunostaining in the aortic
sinus. This could be due to a simultaneous decrease in number of
macrophages and plaque area, which would not be reflected in a
percentage measurement. The mRNA level of inflammatory
markers in heart was unaltered, and could explain the unchanged
levels of macrophages. However, mRNA levels were measured in
total heart that may weaken a potential reduction of these
inflammatory markers. The decrease in sinus plaque area, without
a change of macrophages could also be explained by shrinkage of
the lipid-rich core due to fewer lipids, thus the macrophages
decrease in size.
Liver is the main organ regulating lipoprotein metabolism,
including plasma TAG and cholesterol levels, and a high dietary
cholesterol intake has been reported to elevate liver inflammation
[8]. Noteworthy, the plasma concentrations of cholesterol and
TAG were not affected by SPH-treatment. This was accompanied
by unchanged fatty acid oxidation and ACAT activity. These
results are in contrast with previous reports showing cholesterol-
lowering effects of fish protein hydrolysates in both rats and mice
[14,16]. Although gene expressions of Acaca and the D9-desaturase
Scd1 were decreased, it did not affect plasma TAG in apoE2/
2mice. This lack of effect could be explained, at least partially, by
the lower amount of fish protein used in the present study (5%)
compared to previous studies, where 10–25% fish protein
hydrolysate were applied [14,16,17]. In C57BL/6 mice fed 5%
Figure 2. Histological and immunohistochemical characterization of plaques in the aortic sinus in apoE2/2 mice fed a high-fat diet
(control) or a diet with 5% SPH for 12 weeks. Representative photomicrographs and quantification of maximum plaque area (panels A–C).
Representative photomicrographs and quantification of extracellular matrix deposition (panels D–F), Lipid deposition (panels G–I), Macrophages
(panels J–L) and T lymphocytes (panels M–O). The amount of extracellular matrix, lipids, macrophages and T-lymphocytes is expressed as percentage
of the stained area over the total plaque area. Bar in panel A = 100 mm. Positive area (%) refers to the percentage of the plaque area occupied by
connective tissue, lipids, macrophages and T lymphocytes, respectively. Data are shown as means 6 SD for 6 mice for each diet and unpaired t-test
was used to detect significance (*P,0.05).
doi:10.1371/journal.pone.0097598.g002
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SPH for 6 weeks, a 32% decrease in plasma TAG has been found,
but no change in plasma cholesterol (data to be published). Thus,
in the present study, the disturbed plasma lipid transport in the
apoE2/2 mouse model might have interfered with the potential
TAG-lowering mechanism of SPH, while cholesterol-lowering
effect might not be expected at this dose. A lower cholesterol level
has been observed in animal studies when taurine was added in the
diets [32,33]. However, in our study, the cholesterol level was not
affected after intervention despite the presence of taurine in the
SPH-diet.
The plasma level of NEFAs was unchanged by SPH adminis-
tration and only minor alterations were observed in plasma fatty
acid composition. During the 12 weeks of feeding the plasma level
of MUFAs was slightly lower in the SPH-fed group, but this was
probably not of biological significance. Total n-6 PUFAs in plasma
was higher in SPH-fed mice at the end-point measurement.
Figure 3. Levels of mRNA expression in aorta and inflammatory mediators in plasma in apoE2/2 mice fed a high-fat diet (control) or
a diet with 5% SPH for 12 weeks. (A) The gene expressions of the inflammatory markers Icam1, Vcam1, Nos2 and Mcp1 were measured in pooled
aortic arch from six mice. Inflammatory markers in blood samples collected at day 77 of treatment were analysed (B) IL-1b, (C) IL-6, (D) IL-10, (E) TNF-a,
(F) GM-CSF and bars represent means6 SD of 4 pooled samples of 3 mice for each diet. Unpaired t-test was used to assess statistical significance and
results significantly different from control are indicated (*P,0.05, **P,0.01).
doi:10.1371/journal.pone.0097598.g003
Figure 4. Hepatic gene expression in apoE2/2 mice fed a high-fat diet (control) or a diet with 5% SPH for 12 weeks. Hepatic mRNA
levels of (A) Acaca and (B) Scd1. Data for gene expressions are shown as mean values relative to control6 SD for 4 mice for each diet. Mann-Whitney
test was used to assess statistical significance (*P,0.05).
doi:10.1371/journal.pone.0097598.g004
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Arachidonic acid and oleic acid was increased and decreased in
the SPH group and controls, respectively, after the feeding period.
The increase in arachidonic acid and linoleic acid with a
simultaneously decrease in oleic acid might be due to increased
synthesis of arachidonic acid and linoleic acid from their precursor
oleic acid. Although arachidonic acid is considered pro-inflam-
matory [34], we detected reduction in plaque area in aortic arch
and sinus, suggesting that SPH reduced atherosclerotic activity
independent of the plasma arachidonic acid level. n-3 PUFAs, the
n3/n6 ratio and anti-inflammatory index were not affected by
SPH feeding, which is in contrast to previous findings [35].
However, as stated previously, in the current study we used a
smaller amount of fish protein (5% vs. 15%) and the mouse model
could also influence the effect on fatty acid composition. Knockout
of the apoE gene causes an abnormal plasma lipid composition
and metabolism, which apparently this SPH-diet cannot counter-
act.
Cytokines play a key role in the progression of atherosclerosis
and it was of interest to note that the reduction in plaque area in
the aortic arch was accompanied by a lowering of inflammatory
markers in plasma, as reported in another study using salmon
protein on inflammatory bowel disease in rats [18]. Peroxisome
proliferator-activated receptors (PPAR), which are ligand-depen-
dent transcriptional factors regulating both fatty acid [36] and
amino acid metabolism [37], are shown to exert anti-inflammatory
potential by inhibiting expression of cytokines and other pro-
inflammatory factors [38]. The mechanism is unclear, but Zhu
et al. has recently shown that marine peptides may act as PPAR-
agonists and exert an anti-inflammatory effect [39]. Altogether,
these results suggest that SPH administration might prevent
atherosclerotic development by inhibiting activation of systemic
inflammation.
A small dose of SPH 3.5% in rats has been shown to potentially
exert antioxidant activities by reducing markers for oxidative stress
in colon [18]. In the current study, gene expressions of the
Table 1. Plasma lipids in apoE2/2 mice fed a high-fat casein diet (control) or a high-fat diet with 5% SPH after 77 days of dietary
treatment.
1Lipid class Day 77
Control SPH
Cholesterol 1260.9 1161.0
TAGs 1.460.1 1.360.1
Phospholipids 3.060.1 3.060.1
NEFAs 0.860.2 1.160.1*
Cholesteryl esters 8.160.8 7.960.8
Free Cholesterol 3.760.1 3.460.2
1mmol/L.
Data are shown as mean 6 SD (n= 4).
Abbreviations: NEFA, non-esterified fatty acid; SPH, salmon protein hydrolysate; TAG, triacylglycerol.
*P,0.05 vs. control.
doi:10.1371/journal.pone.0097598.t001
Table 2. Plasma fatty acid composition in apoE2/2 mice fed a high-fat casein diet (control) or a high-fat diet with 5% SPH after 77
days of dietary treatment.
1Fatty acids Control SPH
gSFAs 3260.5 3460.5
gMUFAs 3160.4 3060.4*
C18:1n-9 (oleic acid) 2560.4 2460.5
C18:1n-7 (vaccenic acid) 1.360.0 1.260.0*
n-6 PUFAs 2860.4 3060.4**
C18:2n-6 (linoleic acid) 1560.1 1660.2***
C20:4n-6 (arachidonic acid) 1260.4 1360.2*
n-3 PUFAs 6.460.3 6.360.3
C20:5n-3 (eicosapentaenoic acid) 0.5360.0 0.460.0
C22:6n-3 (docosahexaenoic acid) 5.060.3 5.060.2
n-3/n-6 0.260.0 0.260.0*
1Fatty acids (% w/w).
Data are shown as mean 6 SD (n= 4).
Abbreviations: MUFAs, monounsaturated fatty acids; PUFAs, polyunsaturated fatty acids; SFAs, saturated fatty acids; SPH, salmon protein hydrolysate.
*P,0.05 vs. control.
**P,0.01 vs. control.
***P,0.001 vs. control.
doi:10.1371/journal.pone.0097598.t002
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antioxidants Sod1, Catalase and Nos2 in the heart were unchanged
by SPH administration, suggesting that SPH did not affect the
antioxidant defence system in the heart of apoE2/2 mice.
Although the present study has some limitations, such as absent
protein data on inflammatory mediators within the aortic lesions,
it gives indication that a salmon protein source may have a
protective role in atherosclerotic development through mecha-
nisms linked to inhibition of inflammation, and not directly related
to plasma lipid changes. Although the apoE2/2 mice model has
been used extensively in experiments studying atherosclerosis as it
gives the opportunity to study genetic influence on atherosclerosis
without using a high-fat diet rich in cholesterol, it is also a
challenging model to use. These mice develop severe atheroscle-
rosis due to accumulation of VLDL in plasma carrying most of the
cholesterol. VLDL, containing apoB-48, is considered more
atherogenic than the apoB-100-containing LDL. High plasma
levels of LDL are also most present in humans with atherosclerosis,
therefore in future studies it would be of interest to test this SPH in
LDLr2/2 mice.
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